Surface Oncology, Inc. (SURF)
$0.957
Rating:
Recommendation:
-
| Symbol | SURF |
|---|---|
| Price | $0.957 |
| Beta | 1.615 |
| Volume Avg. | 0.32M |
| Market Cap | 57.939M |
| Shares () | - |
| 52 Week Range | 0.602-3.83 |
| 1y Target Est | - |
| DCF Unlevered | SURF DCF -> | |
|---|---|---|
| DCF Levered | SURF LDCF -> | |
| ROE | -52.58% | Strong Sell |
| ROA | -36.51% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 60.98% | Buy |
| P/E | - | |
| P/B | 0.50 | Buy |
Latest SURF news
About
Download (Excel)Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 targeting the chemokine receptor CCR8. Surface Oncology, Inc. has a license agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited to develop, manufacture, and commercialize antibodies that targets SRF813; and license agreement with Vaccinex, Inc. to develop, manufacture, and commercialize antibodies, which targets SRF114. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.